Argonautic iSelect Special Situations Fund I SP (AISS)

Euclises is a drug discovery and development technology platform designed to offer novel pain and cancer medications. The company's platform focuses on developing novel cyclooxygenase-2 (COX-2) inhibitors for use in the oncology setting, as well as develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform, enabling physicians to access advanced new molecules in combinations with both immune checkpoint and EGFR inhibitors to treat cancer.